Skip to content
Menu

Replimune Group, Inc. REPL

Full chart Compare
Set alert

Price alert · REPL

All alert types
19.15 USD -0.08 (-0.42%)

As ofNov 20, 2026, 11:20 AM EST

18.70 Day range 19.24
1.50 52-week range 23.54
YTD
+97.02%
1 year
+112.54%

5D -0.92 (-4.38%)

202122FriMonTueWedThu20.10
Market cap
1.82B
EPS (ttm)
-2.79
Shares out
94.80M
Forward P/E
-28.67
YTD return
+97.02%
1-year return
+112.54%
50-day average
15.10
200-day average
10.19
Enterprise value
1.70B
Price / book
8.90
Volume
495.22K
Avg volume
2.49M
Open
18.82
Previous close
19.23
Day's range
18.70 – 19.24
52-week range
1.50 – 23.54
Beta
0.93
Analysts
Buy
Price target
25.50 (+33.2%)
Earnings date
Feb 2, 2027

Key statistics

Free cash flow
-148.30M
Total cash
307.83M
Total debt
127.19M
Return on equity
-115.80%
Short % of float
36.13%

Fundamental scorecard

4 of 25 checks passed on REPL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
REPL Revenue — quarterly 0
REPL Net income — quarterly -57.12M
REPL EPS — quarterly -0.54

Earnings

REPL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 2, 2027Dec 30, 2026-0.56———
Oct 28, 2026Sep 30, 2026-0.784-0.54+0.24+31.12%
Aug 14, 2026Jun 30, 2026-0.694-0.72-0.03-3.75%
Jun 29, 2026Mar 31, 2026-0.73-0.76-0.03-4.11%
Feb 3, 2026Dec 31, 2025-0.7683-0.770.00-0.22%
Nov 6, 2025Sep 30, 2025-0.87-0.90-0.03-3.45%

Upgrades / downgrades

REPL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026Leerink PartnersmainOutperformOutperform
Aug 26, 2026JP MorganmainOverweightOverweight
Aug 7, 2026JP MorganmainOverweightOverweight
Aug 7, 2026WedbushupNeutralOutperform
Aug 4, 2026Leerink PartnersupMarket PerformOutperform
Jul 31, 2026WedbushmainNeutralNeutral

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on REPL — it syncs with the Stock Master app.

Insider holders

REPL insider holders
InsiderRelationLatest transactionDateShares held
ASTLEY-SPARKE PHILIPDirectorStock GiftAug 19, 20261,362,410
DHINGRA KAPILDirectorConversion of Exercise of derivative securityNov 1, 202621,669
HILL EMILY LUISAChief Financial OfficerSaleNov 15, 2026201,143
PATEL SUSHILChief Executive OfficerSaleNov 15, 2026659,125
SARCHI CHRISTOPHEROfficerSaleMay 31, 2026180,962
SCHWENDENMAN ANDREWOfficerSaleNov 15, 202697,277

Institution ownership

REPL institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP11.65%11,045,336212.40MSep 29, 2026
Blackrock Inc.9.28%8,799,007169.20MSep 29, 2026
RTW Investments LP8.96%8,491,525163.29MSep 29, 2026
Montanova Capital LLC8.63%8,183,248157.36MSep 29, 2026
Boxer Capital Management, LLC4.51%4,278,15982.27MSep 29, 2026
State Street Corporation4.40%4,174,26080.27MSep 29, 2026

Fund ownership

REPL fund ownership
Holder% heldSharesValueReported
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.62%2,487,95847.84MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.20%2,083,49440.07MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.08%1,972,68437.93MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.92%870,56716.74MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.90%854,08916.42MJun 29, 2026
iShares Trust-iShares Russell 2000 Value ETF0.80%761,65914.65MSep 29, 2026